PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit